A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Firas Kaddouh
Sponsor
IQVIA RDS Inc.
Unit
Neurology